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Peter Reimer1* and Shanta Chawla2Abstract
Peripheral T/NK-cell lymphomas (PTCL) are rare malignancies with a poor prognosis. Due to the lack of randomised
studies, standard therapy has not been established. First-line treatment with anthracycline-based polychemotherapy
followed by consolidation with high-dose therapy and autologous stem cell transplant in responding patients has
demonstrated good feasibility with low toxicity in prospective studies and is widely used in eligible patients. In
relapsed and refractory patients, who are not candidates for transplant approaches, therapeutic options are limited
and are usually palliative. Several new agents are currently under investigation to improve the outcome of PTCL in
the first line and salvage settings. Belinostat, a histone deacetylase (HDAC) inhibitor, has demonstrated broad
antineoplastic activity in preclinical studies, and promising results in advanced relapsed/refractory lymphomas.
Here, we report the case of a 73 year old patient with heavily pre-treated refractory PTCL in complete remission
with belinostat for 39 months.
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Peripheral T-cell lymphomas (PTCL) are rare malignan-
cies representing approximately 10%-15% of all non-
Hodgkin’s lymphomas (NHL) in Western countries
[1-3]. With the exception of ALK (anaplastic lymphoma
kinase) positive anaplastic large cell lymphoma, PTCL
exhibits an aggressive course and patients have a poor
outcome after conventional chemotherapy [4-7] with a
median overall survival (OS) of 9 to 42 months [8-10]. Al-
though anthracycline-based regimens are widely used as
first-line therapy, their benefit has not been established
prospectively in PTCL. In the absence of randomised tri-
als, high-dose therapy with autologous stem cell trans-
plantation is widely used as consolidation. For relapsed or
refractory PTCL, autologous and allogeneic stem cell
transplantation is the standard of care for eligible patients.
However, chemotherapy-refractory patients are not good
candidates for this approach. Several prospective trials* Correspondence: p.reimer@kliniken-essen-sued.de
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prognostic factor in the transplant setting and patients
without at least a partial remission at transplantation have
a poor outcome following either autologous or allogeneic
stem cell transplantation. New approaches that include
novel agents are urgently needed, and several different
agents are currently under investigation to improve the
outcome of patients with PTCL.
Belinostat is a potent inhibitor of histone deacetylase
(HDAC) enzymes, which alter acetylation levels of his-
tone and non-histone proteins. HDAC enzymes regulate
multiple cellular processes and play a role in cancer cell
proliferation and survival. Belinostat has demonstrated
broad antineoplastic activity in preclinical studies and
has been investigated in several Phase I and II studies in
patients with solid and hematologic neoplasms. In 20
patients with refractory and relapsed PTCL, Pohlman
et al. reported an overall response rate of 25% with a
median duration of response of about 5 months [11].
Preliminary results of the large multicenter, open-
label belinostat trial in relapsed and refractory PTCL
were recently presented at the Annual Meeting of the
American Society of Oncology [12].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
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Figure 1 CT scan of the neck before starting belinostat therapy
(January 2010) showing multiple lymph nodes mainly at the
right site of the neck (arrow).
Figure 2 CT scan of the neck after 2 cycles of belinostat
(April 2010) showing a complete response.
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with refractory PTCL, who remains in complete remis-
sion following treatment with belinostat for 39 months.
Case presentation
In June 2009, a 69 year old female patient was diagnosed
with PTCL not otherwise specified (PTCL-NOS) after
complaining of hoarseness. Staging procedures re-
vealed a single manifestation with involvement of the
epipharynx with no evidence of B symptoms (Ann
Arbor stage IE A). The international prognostic index
(IPI) and the prognostic index for T-cell lymphoma
(PIT) were low (age above 60 years as the only risk factor).
The patient was otherwise healthy with no relevant con-
comitant diseases. Following two cycles of chemotherapy
with CHOP-21 (cyclophosphamide 750 mg/m2 day 1, vin-
cristine 1.4 mg/m2 day 1, doxorubicin 50 mg/m2 day 1,
and prednisolone 100 mg absolute day 1–5), she achieved
a partial remission, but showed progressive disease after
completing six cycles CHOP-21 with new enlarged cer-
vical lymph nodes on both sides of the neck. The patient
was scheduled for myeloablative chemotherapy with au-
tologous stem cell transplant using a DHAP protocol (cis-
platin 100 mg/m2 day 1, cytarabine 2.000 mg/m2 bid
day 2, and dexamethasone 40 mg absolute days 1–4) for
tumor reduction and stem cell collection. Following two
courses of DHAP, the patient again had progressive dis-
ease showing further increase of the cervical lymph nodes
and new supraclavicular lymph nodes. A third line chemo-
therapy regimen with DexaBEAM (dexamethasone 8 mg
absolute TID day 1–10, carmustine 60 mg/m2 day 2, mel-
phalan 20 mg/m2 day 3, etoposide 75 mg/m2 day 4–7, and
cytarabine 100 mg/m2 BID day 4–7) did not result in
lymphoma remission; due to chemo-refractory disease,
the myeloablative concept was abandoned (Figure 1).
The patient was enrolled in January 2010 in the multi-
center, open-label BELIEF-trial (Phase II study PXD101-
CLN-19). Belinostat was started at a dose of 1000 mg/m2
for days 1–5 in a 21 day cycle. In April 2010 following two
cycles of belinostat, the patient achieved a complete re-
sponse (CR, Figure 2). After 1 year of belinostat therapy
(~ 12 cycles), the interval between cycles was extended
from 21 days to 42 days due to the long lasting remission,
and to avoid potential toxicities. The patient has received
a total of 28 cycles with the last cycle completed in
December 2012, and maintains a CR at her last follow-up
in July 2013.
In general, belinostat therapy was tolerated and ad-
ministered for 28 cycles. Hematologic side effects were
mild without any toxicity more than CTC grade 2. How-
ever, after cycle 2 the patient developed > 2 grade non-
hematologic toxicity: CTC grade 3 relapsing bipulmonary
alveolitis which was successfully treated with steroids:
CTC grade 3 repeated episodes of Clostridium difficiletoxin-associated diarrhoea during the first 4 months
of treatment, that responded to metronidazole: CTC
grade 3 antibiotic resistant atypical pneumonia while
on steroid medication, that responded to treatment
with voriconacole, suggesting pulmonary fungal infec-
tion. All of the non-hematologic adverse events ex-
cept for the alveolitis were not considered related to
belinostat treatment.
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Here we report a patient with chemo-refractory PTCL,
status post 2 cycles of CHOP-21, 2 cycles of DHAP, and
1 cycle of DexaBEAM, who achieved a remarkably long
lasting CR (39 months) after treatment with the novel
HDAC inhibitor, belinostat. After attaining a CR follow-
ing 2 cycles of belinostat and receiving a total of 28 cy-
cles, the patient has remained disease-free for 8 months
after treatment discontinuation. To date, this is by far
the longest period a patient has been treated with
belinostat, and is the first report of durable response
with this agent in relapsed or refractory PTCL.
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